Have you ever wanted to get recognition for outstanding success in technology transfer? Perhaps you just want to share your innovative technology transfer approaches with the broader federal technology transfer community? Well, your timing is perfect! The Federal Laboratory Consortium (FLC) will be

Spravato ® is the first FDA approved prescription nasal spray for adults who suffer from treatment-resistant depression (TRD). Spravato was developed by Janssen Therapeutics from technology developed from a collaboration between the National Institute of Mental Health (NIMH), Yale University and

Traumatic Brain Injuries (TBI) are a major cause of death and disability. Current therapies to treat TBIs with neuroprotective agents are often limited by ability to achieve therapeutic concentrations of the therapeutic agent in the brain. Inventors at the National Institute of Neurological